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High-level DNA amplifications are common genetic aberrations
in B-cell neoplasms
Abstract
Gene amplification is one of the molecular mechanisms resulting in the up-regulation of gene
expression. In non-Hodgkin's lymphomas, such gene amplifications have been identified rarely. Using
comparative genomic hybridization, a technique that has proven to be very sensitive for the detection of
high-level DNA amplifications, we analyzed 108 cases of B-cell neoplasms (42 chronic B-cell
leukemias, 5 mantle cell lymphomas, and 61 aggressive B-cell lymphomas). Twenty-four high-level
amplifications were identified in 13% of the patients and mapped to 15 different genomic regions.
Regions most frequently amplified were bands Xq26-28, 2p23-24, and 2p14-16 as well as 18q21 (three
times each). Amplification of several proto-oncogenes and a cell cycle control gene (N-MYC (two
cases), BCL2, CCND2, and GLI) located within the amplified regions was demonstrated by Southern
blot analysis or fluorescence in situ hybridization to interphase nuclei of tumor cells. These data
demonstrate that gene amplifications in B-cell neoplasms are much more frequent than previously
assumed. The identification of highly amplified DNA regions and genes included in the amplicons
provides important information for further analyses of genetic events involved in lymphomagenesis.
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Gene amplification is one ofthe molecular mechanisms
resuldng in the up-regulation of gene expression. In
non-Hodgkin's lymphomas, such gene amplifications
have been identified rarely. Using comparative genomic
hybridization, a technique that has proven to be very
sensidve for the detecdon of high-level DNA amplifica-
tions, we analyzed 108 cases of B-cell neoplasms (42
chronic B-cell leukemias, 5 mantle cell lymphomas,
and 61 aggressive B-cell ymphomas). Twenty-four high-
level amplifcations were identified in 13% of the pa-
tients and mapped to 15 different genomic regions. Re-
gions most frequently amplifed were bands Xq26-28,
2p23-24, and 2p14-16 as well as 18q21 (three times
each). Amplifcaton of several proto-oncogenes and a
cell cycle control gene (N-MYC (two cases), BCL2,
CCND2, and GLI) located within the amplied regions
was demonstrated by Southern blot analysis or fluores-
cence in situ hybridization to interphase nuclei of tu-
mor cells. These data demonstrate that gene amplifica-
tions in B-cell neoplasms are much more fiequent than
previously assumed. The identification of highly ampli-
fied DNA regions and genes inchlded in the amplicons
provides important information for further analyses of
genetic events involved in lymphomagenesis. (Am J
Pathol 1997, 151:335-342)
Alterations of proto-oncogenes play a key role in the
development of malignant tumors. One of the mecha-
nisms for activating proto-oncogenes is gene amplifica-
tion resulting in an enhanced expression of the corre-
sponding gene product (for review see Ref. 1). Clinically,
gene amplifications often have been associated with a
more aggressive tumor phenotype and a shorter overall
survival in several tumor types.2 Whereas gene amplifi-
cation is known to occur frequently in many solid tumors,
eg, in neuroblastoma or in breast cancer, in non-
Hodgkin's lymphoma (NHL) it has been considered a
rare event. Using banding techniques, the cytogenetic
hallmarks of DNA amplification, homogeneously staining
regions or double minute chromosomes, have been re-
ported in only 19 of more than 3500 NHL cases.3
However, recent studies using the technique of com-
parative genomic hybridization (CGH)4,5 in small groups
of patients suggested a much higher frequency of high-
level DNA amplifications.69 CGH data led to the identi-
fication of REL amplifications in diffuse large-cell lympho-
mas10 and primary mediastinal B-cell lymphomas.7
These findings underline the usefulness of CGH for the
detection of high-level DNA amplifications. 11,12
In the present study, we applied CGH to 108 cases
with B-cell neoplasms to identify and map high-level DNA
amplifications. The chromosomal map positions of the
amplified sequences were used as entry points to study
the involvement of specific genes by Southern blot anal-
ysis and fluorescence in situ hybridization (FISH).
Materials and Methods
Tumor Specimens
Tumor samples of 108 patients with B-cell neoplasms
classified according to the REAL classification13 were
analyzed by CGH. For 15 cases of Burkitt's lymphoma (all
previously untreated), 5 cases of mantle cell lymphoma
(3 previously treated), and 42 cases of chronic B-lympho-
cytic leukemia (B-CLL; 15 previously treated), frozen tu-
mor material was used. In 46 patients with aggressive
lymphomas other than Burkitt's lymphoma (all previously
untreated), only limited amounts of paraffin-embedded
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Table 1. CGH Data of B-Cell Neoplasms with High-Level DNA Amplifications
CGH data"
High-level
Case Diagnosis amplification Low-level changes
AMP1 DLC-B amp(Xq26-28), enh(5q23q31,6p,7q11q22), dim(1p21p31,6q,9p21p24,13q21q31)
amp(12q13-14)
AMP2 FCL, Iv amp(18q21-22) enh(3q1 1q27,4p,4q12q21 ,7p,7q1 1q22,11,12), dim(6q)
AMP3 FCL, Iv amp(1 4q21-24) enh(Xp2l p22,Xq2l q28,2p1 3p21 ,6p22p35,7p1 5p21 ,1 8q1 1 q22)
AMP4 FCL, Iv amp(Xq21-24) enh(7p13p21,7q21q36,9p21p24,11), dim(9q12q21,17p)
amp(3q 12-13)
amp(4q32-35)
AMP5 FCL, lv amp(2p22-24) dim(6q16q21)
AMP6 FCL, Iv amp(19q13)
AMP7 DLC-B amp(Xpl 1-21)
AMP8 FCL, Iv amp(2p13-16) enh(1q21q42,7q1 1q21,16,19,X)
AMP9 FCL, Iv amp(2p14-16) enh(1q24q44,5q13q23,7p,13q14q32,14q13q32)
AMP10* MCL amp(Xq26-28) dim(8p21 p23, 1 Op13p15,13q1 3q34)
amp(2p23-24)
amp(3q26-29)
amp(1 8q21-23)
amp(19q13)
AMP1 1 BL amp(2p23-25) t
AMP12 FCL, Iv amp(2p14-16) enh(3q25q29)
amp(8q23-24)
amp(1 5q23-24)
amp(1 8q21-23)
AMP13 B-CLL amp(14q31-32) enh(X,8), dim(2q36q37)
AMP1 4* MCL amp(Xq27-28) enh(3q21q29,12q), dim(13q14q34)
DLC-B, diffuse large B-cell lymphoma; FCL, Iv, follicle center lymphoma, large cell variant; MCL, mantle cell lymphoma; BL, Burkitt's lymphoma; B-
CLL, chronic B-lymphocytic leukemia. '9CGH data are presented according to the ISCN45: amp, high-level DNA amplification; enh, enhanced signal
intensity (ie, gain of chromosomal material); dim, diminished signal intensity (ie, loss of chromosomal material).
*Only cases AMP10 and AMP14 have been treated before molecular cytogenetic analysis.
tin this case, degenerate oligonucleotide-primed (DOP-) PCR16 was necessary before CGH to obtain a sufficient amount of genomic DNA. Due to
inconsistencies in repeated experiments, low-level copy number changes were not scored in this case. However, the high-level amplification mapping
to bands 2p23-25 was detected in each experiment. This finding was also confirmed by the demonstration of a greater than 100-fold amplification of
the N-MYC proto-oncogene in this case (see also Figure 3B).
tissue samples were available for DNA isolation and sub-
sequent CGH experiments. Histopathological diagnoses
of the 14 cases with high-level DNA amplifications are
listed in Table 1.
Comparative Genomic Hybridization
Genomic DNA was prepared from fresh tumor tissue as
described14 using proteinase K digestion and phenol-
chloroform extraction. From paraffin sections, genomic
DNA was isolated according to the method described by
Isola and co-workers.15 In one sample (AMP11), a uni-
versal polymerase chain reaction protocol16 was neces-
sary to obtain a sufficient amount of DNA. CGH was
performed as reported previously.17 Briefly, tumor DNA
was labeled with biotin-16-dUTP (Boehringer Mannheim,
Mannheim, Germany), and normal human control DNA
was labeled with digoxigenin-1 1-dUTP (Boehringer
Mannheim) by a standard nick translation reaction. One
microgram of biotin-labeled tumor DNA, one microgram
of digoxigenin-labeled control DNA, and seventy micro-
grams of human Cot-i-DNA (BRL Life Sciences, Gaith-
ersburg, MD) were co-hybridized to slides with meta-
phase cells prepared from blood of a healthy donor. After
hybridization for 2 to 3 days and post-hybridization
washes, control and test DNAs were detected via rhoda-
mine and fluorescein isothiocyanate (FITC), respectively.
For identification, chromosomes were counterstained
with 4,6-diamidino-2-phenylindole (DAPI).
Digital Image Analysis
Digital image analysis was performed using an epifluo-
rescence microscope (Axioplan, Zeiss, Jena, Germany)
and the commercially available image analysis systems
ISIS (MetaSystems, Altiussheim, Germany) or CYTOVI-
SION (Applied Imaging, Sunderland, UK). Sensitivity and
specificity of both systems were validated by applying a
series of cases with well defined abnormalities to the
systems. Furthermore, in the 42 cases with CLL, CGH
data were compared with interphase cytogenetics of at
least five chromosomal regions for each case, proving
the high accuracy of these evaluation software programs
(manuscript in preparation). Ratio values of 1.25 and
0.75, which have been proven to provide robust criteria
for diagnosing over- and underrepresentations,18-20
were used as upper and lower thresholds for the identi-
fication of chromosomal imbalances. Overrepresenta-
tions were considered as high-level amplifications when
the fluorescence ratio values exceeded 2.0 or when the
FITC fluorescence showed strong focal signals and the
corresponding ratio profile was diagnostic for overrepre-
sentation. Assignment of highly amplified sequences to
chromosomal bands was performed by comparison of
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signal intensities and DAPI banding on individual chro-
mosomes.
Fluorescence in Situ Hybridization
FISH analysis of interphase nuclei was performed using
the following probes: the cosmid probe "GLI" and the
alphoid satellite probe D12Z3 (both obtained from Oncor,
Gaithersburg, MD) were used to investigate the amplifi-
cation of the GLI proto-oncogene. For characterization of
an amplification unit at 14q32, probes cos-Ca2 containing
the Ca2 constant gene segment of the immunoglobulin
heavy chain (IgH) locus21 and YAC Y6 containing vari-
able region gene segments of the IgH locus22-24 were
used. For evaluation of FISH experiments, at least 200
nuclei were analyzed. Criteria for gene amplification were
either the presence of a tight cluster of signals in addition
to one or more normal hybridization spots or a signal ratio
of .4 of the respective gene probe relative to a simulta-
neously hybridized probe for the centromeric region of
the same chromosome (see also Ref. 25). In all cases
with amplifications diagnosed by FISH, either of these
criteria was fulfilled in at least 25% of interphase nuclei.
Southern Blot Analysis
Southern blot analysis was performed using standard
procedures.14 Briefly, 8 Ag of genomic DNA was di-
gested with EcoRI, separated by agarose gel electro-
phoresis, and transferred to nylon membranes (Boeh-
ringer Mannheim). The membranes were hybridized with
the following DNA probes labeled by random priming
with [32P]dCTP: a 2.8-kb BCL2-specific probe (Oncor), a
1.0-kb N-MYC-specific probe (Oncor), and pXcD2, a cy-
clin D2 (CCND2)-specific cDNA probe26 (kindly provided
by Drs. P. Jansen-DOrr, Deutsches Krebsforschungszen-
trum, Heidelberg, Germany, and B. Henglein, INSERM U
75, Paris, France). Probe pMDM2A, a 600-bp fragment
specific for MDM2, and a 534-bp nucleotide probe for
CDK4 were kindly provided by Dr. G. Reifenberger, Uni-
versity of Dusseldorf, Germany.27'28 For control hybrid-
izations, the genomic fragment gMHC-1-D from the car-
diac B3-myosin heavy chain gene MYH7, located on
chromosome band 14q12-q13, was used.29 Determina-
tion of gene dosage was performed by densitometric
measurements of the hybridization bands obtained with
the target probe and MYH7. For normalization of hybrid-
ization signals, an equal amount of normal human lym-
phocyte DNA was included in each experiment.
Results
Comparative Genomic Hybridization
Using CGH, 24 high-level DNA amplifications were iden-
tified and mapped to 15 different genomic regions in 14
of the 108 NHLs (13% of the cases). In these amplified
regions, there was either a fluorescence ratio value
greater than 2.0 or a strong focal FITC signal with a
corresponding ratio profile diagnostic for overrepresen-
tation (see also Materials and Methods). The chromo-
somal localizations of the highly amplified DNA se-
quences are summarized in Figure 1. Apart from the
high-level amplifications, the most frequent chromosomal
imbalances in these cases were gains (characterized by
fluorescence ratio values >1.25 without fulfilling the cri-
teria for a high-level amplification) on chromosomes 7 (six
cases) and X (three cases) and on the long arm of chro-
mosome 3 (three cases) as well as losses (defined by
fluorescence ratio values <0.75) on chromosome arms
6q and 13q (three cases each). The complete CGH data
of these 14 cases are summarized in Table 1.
High-level amplifications were more frequent in ag-
gressive lymphomas (11 of 61 cases, 18%; whole series:
14 of 108, 13%). The most frequently affected genomic
regions were chromosomal bands 18q21-22, 2p23-24,
2p14-p16, and Xq27-q28, which were highly amplified in
three instances each. In two cases, amplifications map-
ping to 19q13 were observed. The other DNA amplifica-
tions were located at chromosomal bands Xpl 1-21,
Xq21-24, 3q12-13, 3q26-29, 4q32-35, 8q23-24,
12q 13-14, 14q21-24, 14q31-32, and 15q23-24. Among
the 14 patients with high-level DNA amplifications, four
exhibited more than one amplification site (see Table 1).
A partial CGH karyotype of case AMP12 with four ampli-
fication sites is shown in Figure 2.
Southern Blot and FISH Analysis
To identify genes included in the amplicons, databases
were screened for candidate genes in the regions exhib-
iting amplification sites. In five cases, genes included in
the amplicons were identified (see Table 2).
The proto-oncogene BCL2 was an obvious candidate
gene for cases with amplification units mapping to band
18q21. Southern blot analysis of case AMP10, the only
one of these cases for which sufficient frozen material
was available, revealed a fivefold amplification of the
BCL2 gene. High-level DNA amplifications mapping to
bands 2p23-24 were observed in three cases (AMP5,
AMP10, and AMP11). As this is the localization of the
proto-oncogene N-MYC, Southern blot analysis with an
N-MYC-specific probe was performed in the two cases
for which DNA of sufficient quality was available. Densi-
tometric evaluation of the N-MYC and control (MYH-7)
signals revealed a greater than 100-fold and a 4-fold
amplification of this gene in cases AMP1 1 and AMP10,
respectively (see Figure 3B). In case AMP13, a high-level
amplification was identified at 14q31-32. FISH analysis
using probes cos-Ca2 and Y6 showed multiple co-local-
ized cos-Ca2 and Y6 signals, indicating an amplification
of DNA sequences derived from the IgH locus.
To identify amplified proto-oncogenes on chromo-
some 12, the gain of which is particularly frequent in
B-cell neoplasms, we also investigated two cases,
which were previously published by our group.6,8'30 A
CLL case exhibited amplified DNA sequences map-
ping to two distinct loci on the short arm of chromo-
some 12, namely, bands 12p1 1-1 2 and 12p13 (case A,
see Table 2), the latter of which contains the cyclin D2
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Figure 1. Chromosomal localizations of high-level DNA amplifications in 108 cases of B-cell neoplasms. High-level DNA amplifications are symbolized by dots
on the right side of the ideograms. For each amplification, the respective case number is indicated.
gene (CCND2). Subsequent Southern blot analysis
with a CCND2-specific probe showed a high copy
number increase of CCND2, proving an amplification of
this gene.
In addition to case AMP1, an amplification site map-
ping to bands 12q13-14 was also present in a follicle
center lymphoma (case B). In this case, nuclei were
available for FISH using a cosmid probe specific for the
proto-oncogene GLI. In 25% of the nuclei, FISH revealed
a high-level amplification of this gene. This was demon-
strated by simultaneous hybridization of the GL/-specific
probe and an alphoid probe specific for the centromeric
and paracentromeric repetitive sequences of chromo-
some 12 (D12Z3) (see Figure 3A). In this case, additional
Southern blot experiments were performed using probes
for the candidate genes CDK4 and MDM2, which are in
close proximity to GLI. In both experiments, normal copy
numbers of these genes were demonstrated.
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Figure 2. Partial CGH karyotype of case AMP12. Images were acquired and evaluated using the CYTOVISION software package (Applied Imaging). Numbers at
the bottom indicate the respective chromosomes. Hybridization with the tumor DNA is visualized via FITC (green), and hybridization with the control DNA is
detected via rhodamine (red). The yellow images on the left side of the ideograms were generated by optical overlay of the green and red images. The band-like
hybridization signals with the tumor DNA (arrows), which are also visible in the optically overlaid images, indicate highly amplified chromosomal sequences. On
the right side of the ideograms, the average ratios of FITC/rhodamine fluorescence are plotted (ratio profiles). The central line indicates a ratio value of 1.0, green
lines to the right indicate ratio values of 1.25 and 1.5, respectively, and red lines to the left indicate ratio values of 0.75 and 0.5.
Discussion
In contrast to many other tumor types,' gene amplifica-
tions were rarely identified in NHL. Based on banding
analyses, only 19 of more than 3500 cases exhibited
homogeneously staining regions or double minutes.3
Even in such cases, the identification of amplified genes
was difficult, mainly because banding data did not pro-
vide any clues with regard to the genomic origin of the
amplified sequences. In one series of nine patients with
cytogenetic evidence for gene amplification, a panel of
DNA probes for 23 proto-oncogenes and the multidrug
Table 2. Identification of Amplified Genes in B-Cell
Neoplasms
Amplified Amplified
Case Diagnosis region(s) gene(s)
AMP10 MCL Xq26-28
2p23-24 N-MYC
3q26-29
18q21-23 BCL2
19q13
AMP11 BL 2p23-25 N-MYC
AMP13 B-CLL 14q31-32 IgH
A* B-CLL 12p11-1 2
12p13 CCND2
Bt FCL, slv 8q24 C-MYC
12q13-14 GLI
MCL, mantle cell lymphoma; BL, Burkitt's lymphoma; B-CLL, chronic
B-lymphocytic leukemia; FCL, siv, follicle center lymphoma, small and
large cell variant.
*Case 22 in Bentz et al.6
tCase 14 in Bentz et al.8; C-MYC amplification has already been
reported in this publication.
resistance gene PGY1 was tested by Southern blot hy-
bridization. In none of the cases was an amplification of
one of these genes demonstrated.31 In contrast, CGH
proved to be very sensitive for the detection of high-level
DNA amplifications.11,12'32 In addition, the amplified se-
quences are mapped within the genome, allowing the
rapid selection of candidate genes. Thus, the identifica-
tion of amplified genes is greatly facilitated.10'25 In the
present study, we analyzed a large number of patients
with B-cell neoplasms and detected high-level DNA am-
plifications in 14 of 108 cases (whole series: 13%; ag-
gressive lymphomas: 18%). The higher frequency of
such amplifications in aggressive lymphomas as com-
pared with indolent lymphomas may indicate a possible
association with a more aggressive tumor phenotype.
On the short arm of chromosome 2, two different re-
gions of amplification were identified, namely, bands
2p14-16 and 2p23-24. Recently, amplifications of the
REL proto-oncogene mapping to bands 2p14-15 have
been reported in aggressive lymphomas.7'10 In contrast,
amplification of genes mapping to bands 2p23-24 have
not been reported in NHL. A candidate gene located in
this region is the N-MYC proto-oncogene, which is am-
plified and overexpressed in several tumor types such as
neuroblastoma, retinoblastoma, and small-cell lung car-
2cinoma. In transgenic mouse models, an association of
N-MYC overexpression and lymphoma development was
demonstrated; similar to C-MYC, N-MYC transgenic mice
develop pre-B- and B-lymphoid malignancies.33'34 In two
of the three NHL cases with amplifications mapping to
2p23-24, Southern blot analysis was performed, and an
amplification of N-MYC was detected. These findings
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Figure 3. A: Fluorescence in situ hybridization
to interphase nuclei of case B (follicle center
lymphoma, small and large cell variant) carry-
ing an amplification mapping to chromosomal
bands 12q13-14. The cosmid probe "GLI" is
detected via rhodamine (red), whereas a cen-
tromere-specific DNA probe for chromosome
12 (D12Z3) is detected via FITC (green). In the
upper cell, four hybridization signals are seen
both for "GLI" and D12Z3, indicating tet-
raploidy. In the lower cell, only two D12Z3
signals are present, whereas eight "GLI" signals
are visible in this focal plain, demonstrating a
GLI amplification in this cell. B, left: Partial
CGH karyotype of case AMP1 1 with a Burkitt's
lymphoma. An intense, band-like hybridization
signal mapping to chromosomal bands
2p23-24 is visible. B, right: Southem blot anal-
ysis of DNA of the same case (left) and DNA
from lymphocytes of a healthy control (con,
right). Probes N-MYC and MYH7 (control) are
marked on the left. Note the intense hybridiza-
tion signal of the N-MYC probe. Densitometric
evaluation revealed a greater than 100-fold am-
plification of N-MYC.
further substantiate a possible role for N-MYC deregula-
tion in lymphomagenesis.
Another frequently affected region was located on the
long arm of chromosome 18 (bands 18q21-22). This
coincides with the chromosomal localization of the BCL2
proto-oncogene, a gene that is known to inhibit apopto-
sis. Deregulation of BCL2 plays an important role in most
follicle center lymphomas and in many cases of diffuse
large-cell lymphoma.35 Amplification of this gene was
reported recently in six cases of diffuse large-cell lym-
phoma.9 In the present study, a BCL2 amplification was
also demonstrated in a case of mantle cell lymphoma.
In one case, a high-level DNA amplification mapping to
bands 14q31-32 was identified. FISH analysis revealed
an amplification of DNA sequences derived from the
immunoglobulin heavy chain gene locus. Such an ampli-
fication of the IgH gene has been described before in a
t(11 ;14)(q13;q32)-positive NHL cell line.36 Rearrange-
ments involving the IgH gene are frequent in B-cell neo-
plasias. In these rearrangements, different proto-onco-
genes are juxtaposed to regulatory sequences of the IgH
gene.37 However, there is no clear evidence of an onco-
genic potential of the IgH gene itself. Thus it remains
unclear whether an increased gene dosage of the IgH
gene is of any pathogenetic relevance. It cannot be ex-
cluded that a proto-oncogene in close proximity to this
locus (eg, TCL 138) might be the target of the amplification
in this case.
Identification of amplified genes on chromosome 12
appeared particularly attractive, because an overrepre-
sentation of this chromosome is a common cytogenetic
finding in B-cell neoplasms.3 Gains of genetic material
derived from the chromosomal region 12q13-14 were
identified frequently both by banding analysis3 and by
DNA Amplifications in B-Cell Neoplasms 341
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CGH.7-9 There are several candidate genes mapping to
12q13-14 including MDM2, CDK4, and GLI.39 So far, no
amplifications of genes mapping to this chromosomal
region were demonstrated in NHL. FISH analysis of case
B with follicle center lymphoma showed a high-level am-
plification of the GLI proto-oncogene, whereas a normal
gene dosage was found for CDK4 and MDM2 by South-
ern blot analysis. This is in contrast to data in malignant
gliomas and sarcomas, where MDM2, CDK4, or SAS
belonged to the critical genomic region in tumors exhib-
iting 12q13-14 amplifications, whereas GLI was co-am-
plified in only a few cases.28'40
On the short arm of chromosome 12, amplifications
have been mapped to bands 12p12 and 12p13.641 In
case A, an amplification of the CCND2 gene was dem-
onstrated. CCND2 is a D-type cyclin implicated in the
regulation of cell cycle progression.42 Amplifications of
this gene were recently reported in two cases of aggres-
sive NHL.41
The other high-level DNA amplifications identified in
this study were mapped to 10 chromosomal regions, 6 of
which (3q12-13, 3q26-29, 4q32-35, 19q13, 14q21-24,
and 15q22-24) have not been described before to con-
tain amplification sites in NHL. Candidate genes located
in these bands include BCL3 (located at 19q13)43 and
BCL6 (located at 3q27),44 which are known to be dereg-
ulated in some types of B-cell neoplasms.
This CGH study revealed a high incidence of high-level
DNA amplifications in B-cell neoplasms and provided
information that allowed the identification of amplified
genes in several cases using a candidate gene ap-
proach. Although additional studies are required to elu-
cidate the pathogenetic consequences of these amplifi-
cations, our findings indicate a possible role of proto-
oncogenes in lymphomagenesis, alterations of which
were demonstrated only rarely (CCND2) or not at all (GLI
and N-MYC) in NHL before.
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